<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32304186</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Cortical hyperexcitability evolves with disease progression in ALS.</ArticleTitle><Pagination><StartPage>733</StartPage><EndPage>741</EndPage><MedlinePgn>733-741</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51039</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Cortical hyperexcitability has been established as an early feature of amyotrophic lateral sclerosis (ALS). The evolution of cortical hyperexcitability with ALS progression remains to be fully elucidated. This study aims to investigate changes in cortical function in ALS with disease progression.</AbstractText><AbstractText Label="METHODS">Cortical function assessed by threshold tracking transcranial magnetic stimulation (TMS) along with clinical phenotyping was prospectively undertaken on 444 patients presenting with suspected ALS (345 ALS; 99 neuromuscular mimics). Disease stage was defined as follows: (1) King's clinical staging system and (2) proportion of disease duration statistically categorized into tertials.</AbstractText><AbstractText Label="RESULTS">Cortical hyperexcitability was evident across all ALS stages, being more prominent in later stages of ALS as indicated by increased motor-evoked potential amplitude (P&#xa0;&lt;&#xa0;0.05), as well as longer disease duration as reflected by reduced short-interval intracortical inhibition (P&#xa0;&lt;&#xa0;0.05). Prolonged central motor conduction time was evident with disease progression. These changes were accompanied by reduction in neurophysiological index (P&#xa0;&lt;&#xa0;0.001) and compound muscle action potential amplitude (P&#xa0;&lt;&#xa0;0.01), progressive muscle weakness (P&#xa0;&lt;&#xa0;0.001), and decline in the ALS functional rating scale (P&#xa0;&lt;&#xa0;0.001).</AbstractText><AbstractText Label="INTERPRETATION">This study established an increase in cortical hyperexcitability with increased disease duration in ALS, mediated by cortical disinhibition and direct increase in corticomotoneuronal excitability.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Parvathi</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6935-5852</Identifier><AffiliationInfo><Affiliation>Westmead Clinical School, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higashihara</LastName><ForeName>Mana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Westmead Clinical School, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Bos</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Westmead Clinical School, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geevasinga</LastName><ForeName>Nimeshan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Westmead Clinical School, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0001-9054-026X</Identifier><AffiliationInfo><Affiliation>Brain and Mind Center, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vucic</LastName><ForeName>Steve</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8323-873X</Identifier><AffiliationInfo><Affiliation>Westmead Clinical School, University of Sydney, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019054" MajorTopicYN="N">Evoked Potentials, Motor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009431" MajorTopicYN="N">Neural Conduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009433" MajorTopicYN="N">Neural Inhibition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Prof MCK reports being editor of Journal of Neurology Neurosurgery and Psychiatry. Prof SV reports receiving honoraria from Merck Serono Australia, CSL Australia, and Biogen Pty Ltd Australia. There are no other conflicts of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32304186</ArticleId><ArticleId IdType="pmc">PMC7261748</ArticleId><ArticleId IdType="doi">10.1002/acn3.51039</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Geevasinga N, Menon P, Ozdinler PH, et al. Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nat Rev Neurol 2016;12:651&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">27658852</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Chalabi A, Hardiman O, Kiernan MC, et al. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol 2016;15:1182&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, van den Bos M, Menon P, et al. Utility of threshold tracking transcranial magnetic stimulation in ALS. Clin Neurophysiol Pract 2018;3:164&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6275211</ArticleId><ArticleId IdType="pubmed">30560220</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 2006;129:2436&#x2013;2446.</Citation><ArticleIdList><ArticleId IdType="pubmed">16835248</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Nicholson GA, Kiernan MC. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain 2008;131:1540&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Kiernan MC, Vucic S. Cortical dysfunction underlies the development of the split&#x2010;hand in amyotrophic lateral sclerosis. PLoS One 2014;9:e87124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3901749</ArticleId><ArticleId IdType="pubmed">24475241</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Kiernan MC, Vucic S. Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clin Neurophysiol 2015;126:803&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">25227219</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Bos MAJ, Higashihara M, Geevasinga N, et al. Imbalance of cortical facilitatory and inhibitory circuits underlies hyperexcitability in ALS. Neurology 2018;91:e1669&#x2013;e1676.</Citation><ArticleIdList><ArticleId IdType="pubmed">30282772</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, Simon NG, Geevasinga N, et al. The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. Clin Neurophysiol 2017;128:1075&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">28400096</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Geevasinga N, Yiannikas C, et al. The sensitivity and specificity of threshold&#x2010;tracking transcranial magnetic stimulation for the diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurol 2015;14:478&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">25843898</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchand&#x2010;Pauvert V, Peyre I, Lackmy&#x2010;Vallee A, et al. Absence of hyperexcitability of spinal motoneurons in patients with amyotrophic lateral sclerosis. J Physiol 2019;597:5445&#x2013;5467.</Citation><ArticleIdList><ArticleId IdType="pubmed">31523813</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusu CV, Murakami M, Ziemann U, Triesch J. A model of TMS&#x2010;induced I&#x2010;waves in motor cortex. Brain Stimul 2014;7:401&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">24680789</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Kiernan MC. Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis? Amyotroph Lateral Scler 2012;13:245&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">22424125</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihei K, McKee AC, Kowall NW. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. Acta Neuropathol 1993;86:55&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">8396837</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S, Kollewe K, Grothe C, et al. GABA(A)&#x2010;receptor mRNA expression in the prefrontal and temporal cortex of ALS patients. J Neurol Sci 2006;250:124&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">17011586</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S, Krampfl K, Hashemi F, et al. Distribution of GABAA receptor mRNA in the motor cortex of ALS patients. J Neuropathol Exp Neurol 2003;62:1041&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pubmed">14575239</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanette G, Tamburin S, Manganotti P, et al. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis. Clin Neurophysiol 2002;113:1688&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pubmed">12417221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemann U, Winter M, Reimers CD, et al. Impaired motor cortex inhibition in patients with amyotrophic lateral sclerosis. Evidence from paired transcranial magnetic stimulation. Neurology 1997;49:1292&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pubmed">9371911</ArticleId></ArticleIdList></Reference><Reference><Citation>Prout AJ, Eisen A. The cortical silent period and ALS. Muscle Nerve 1994;17:217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">8114792</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008;119:497&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien MD. Aid to the examination of the peripheral nervous system. 4 ed. London: W.B.Saunders, 2004: 1&#x2013;3.</Citation></Reference><Reference><Citation>Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)&#x2010;PK11195 positron emission tomography study. Neurobiol Dis 2004;15:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, et al. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry 2016;87:628&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Roche JC, Rojas&#x2010;Garcia R, Scott KM, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain 2012;135:847&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286327</ArticleId><ArticleId IdType="pubmed">22271664</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve 2000;23:344&#x2013;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679710</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Howells J, Trevillion L, Kiernan MC. Assessment of cortical excitability using threshold tracking techniques. Muscle Nerve 2006;33:477&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315324</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantello R, Gianelli M, Civardi C, Mutani R. Magnetic brain stimulation: the silent period after the motor evoked potential. Neurology 1992;42:1951&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pubmed">1407578</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Cheah BC, Yiannikas C, Kiernan MC. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol 2011;122:1860&#x2013;1866.</Citation><ArticleIdList><ArticleId IdType="pubmed">21382747</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Lin CS&#x2010;Y, Cheah BC, et al. Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain 2013;136:1361&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pubmed">23616585</ArticleId></ArticleIdList></Reference><Reference><Citation>Geevasinga N, Menon P, Ng K, et al. Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27249331</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Lozano AM, Ashby P. Mechanism of the silent period following transcranial magnetic stimulation. Evidence from epidural recordings. Exp Brain Res 1999;128:539&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">10541749</ArticleId></ArticleIdList></Reference><Reference><Citation>Inghilleri M, Berardelli A, Cruccu G, Manfredi M. Silent period evoked by transcranial stimulation of the human cortex and cervicomedullary junction. J Physiol 1993;466:521&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1175490</ArticleId><ArticleId IdType="pubmed">8410704</ArticleId></ArticleIdList></Reference><Reference><Citation>Siebner HR, Dressnandt J, Auer C, Conrad B. Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle Nerve 1998;21:1209&#x2013;1212.</Citation><ArticleIdList><ArticleId IdType="pubmed">9703450</ArticleId></ArticleIdList></Reference><Reference><Citation>Werhahn KJ, Kunesch E, Noachtar S, et al. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol 1999;517:591&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2269337</ArticleId><ArticleId IdType="pubmed">10332104</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossini PM, Burke D, Chen R, et al. Non&#x2010;invasive electrical and magnetic stimulation of the brain, spinal cord, roots and peripheral nerves: basic principles and procedures for routine clinical and research application. An updated report from an I.F.C.N. Committee. Clin Neurophysiol 2015;126:1071&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6350257</ArticleId><ArticleId IdType="pubmed">25797650</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemann U, Reis J, Schwenkreis P, et al. TMS and drugs revisited 2014. Clin Neurophysiol 2015;126:1847&#x2013;1868.</Citation><ArticleIdList><ArticleId IdType="pubmed">25534482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose&#x2010;ranging study. Lancet Neurol 2018;17:416&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>